Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193268 | 1.00 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL185992 | 1.00 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL15116535 | 0.88 | HDAC8 (0.37) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL19484832 | 0.88 | HDAC8 (0.37) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL13059379 | 0.88 | HDAC8 (0.37) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL19389888 | 0.88 | HDAC8 (0.37) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL6468015 | 0.86 | CNR2 (0.39) | HSD17B10HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL15130409 | 0.86 | CNR2 (0.39) | HSD17B10HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL19131812 | 0.86 | HSD17B10 (0.37) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL1347670 | 0.86 | CNR2 (0.39) | HSD17B10HDAC8CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094953-A | 1, 3-Dihydro-2H-pyrrolo [3,4-c ] quinoline derivatives as cGAS inhibitors for the treatment of inflammatory and/or autoimmune diseases | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026103887-A1 | PROLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 北京康辰药业股份有限公司 | 2026-05-21 | — | — | WO | disclosed |
| EP-4695236-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4608821-A1 | PHARMACEUTICAL COMPOUNDS AS PARP7 AND/OR PARP1 INHIBITORS | Duke Street Bio Limited (GB) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025090774-A1 | CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE | SEAGEN INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025040569-A1 | 1,3-DIHYDRO-2H-PYRROLO[3,4-C]QUINOLINE DERIVATIVES AS CGAS INHIBITORS FOR THE TREATMENT OF INFLAMMATORY AND/OR AUTOIMMUNE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-02-27 | — | — | WO | disclosed |
| CN-114591212-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2024216094-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024115465-A1 | PHARMACEUTICAL COMPOUNDS AS PARP7 AND/OR PARP1 INHIBITORS | Duke Street Bio Limited (GB) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024107778-A1 | NOVEL PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-23 | — | — | WO | disclosed |
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | ELI LILLY AND COMPANY (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | ELI LILLY AND COMPANY (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2015094902-A1 | PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20140221332-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221332-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221332-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2012162635-A1 | METABOTROPIC GLUTAMATE RECEPTORS 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012054510-A1 | OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | PTGER4, PTGER1, GPR4 | HSD17B10 3686/4885HDAC8 938/4885SMN1; SMN2 4442/4885 |
| US-20140221332-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | GRM5, GRIK5, GRM2 | HSD17B10 1045/4885HDAC8 1998/4885SMN1; SMN2 2960/4885 |
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | HSD17B10 1290/4885HDAC8 1523/4885SMN1; SMN2 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.